A detailed history of Wolff Wiese Magana LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Wolff Wiese Magana LLC holds 69 shares of VRTX stock, worth $32,341. This represents 0.02% of its overall portfolio holdings.

Number of Shares
69
Previous 84 17.86%
Holding current value
$32,341
Previous $34,000 17.65%
% of portfolio
0.02%
Previous 0.03%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 18, 2024

SELL
$407.69 - $446.08 $6,115 - $6,691
-15 Reduced 17.86%
69 $28,000
Q4 2023

Jan 16, 2024

SELL
$343.0 - $410.68 $1,715 - $2,053
-5 Reduced 5.62%
84 $34,000
Q3 2023

Oct 30, 2023

SELL
$338.18 - $362.46 $676 - $724
-2 Reduced 2.2%
89 $30,000
Q2 2023

Aug 01, 2023

SELL
$314.42 - $351.91 $5,345 - $5,982
-17 Reduced 15.74%
91 $32,000
Q1 2023

Apr 18, 2023

SELL
$283.23 - $323.1 $566 - $646
-2 Reduced 1.82%
108 $34,000
Q4 2022

Feb 08, 2023

SELL
$285.76 - $321.48 $220,035 - $247,539
-770 Reduced 87.5%
110 $31,000
Q3 2022

Oct 26, 2022

BUY
$273.83 - $305.53 $13,417 - $14,970
49 Added 5.9%
880 $255,000
Q2 2022

Jul 15, 2022

SELL
$234.96 - $292.55 $1.09 Million - $1.36 Million
-4,634 Reduced 84.79%
831 $234,000
Q1 2022

May 09, 2022

SELL
$221.42 - $260.97 $31,663 - $37,318
-143 Reduced 2.55%
5,465 $1.43 Million
Q4 2021

Jan 18, 2022

SELL
$177.01 - $223.45 $9,381 - $11,842
-53 Reduced 0.94%
5,608 $1.23 Million
Q3 2021

Oct 15, 2021

SELL
$181.39 - $202.99 $607,837 - $680,219
-3,351 Reduced 37.18%
5,661 $1.03 Million
Q2 2021

Jul 15, 2021

BUY
$187.49 - $221.1 $30,935 - $36,481
165 Added 1.87%
9,012 $1.82 Million
Q1 2021

Apr 15, 2021

BUY
$207.02 - $241.31 $496,019 - $578,178
2,396 Added 37.14%
8,847 $1.9 Million
Q4 2020

Jan 27, 2021

BUY
$207.01 - $276.09 $1.34 Million - $1.78 Million
6,451 New
6,451 $1.53 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Wolff Wiese Magana LLC Portfolio

Follow Wolff Wiese Magana LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolff Wiese Magana LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolff Wiese Magana LLC with notifications on news.